Fluoroquinolone Susceptibility among Mycobacterium tuberculosis Isolates from the United States and Canada

This publication has 22 references indexed in Scilit:

• Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
  American Journal of Respiratory and Critical Care Medicine, 2004
• Fluoroquinolone Resistance in Patients with Newly Diagnosed Tuberculosis
  Clinical Infectious Diseases, 2003
• Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial
  The Lancet, 2002
• A Prospective, Randomized, Double-Blind Study of the Tolerability of Rifapentine 600, 900, and 1,200 mg Plus Isoniazid in the Continuation Phase of Tuberculosis Treatment
  American Journal of Respiratory and Critical Care Medicine, 2002
• Effectiveness of Once-Weekly Rifapentine and Moxifloxacin Regimens against Mycobacterium tuberculosis in Mice
  Antimicrobial Agents and Chemotherapy, 2001
• Decreased Susceptibility ofStreptococcus pneumoniaeto Fluoroquinolones in Canada
  New England Journal of Medicine, 1999
• Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid
  The Lancet, 1999
• Evaluation of an Intensive Intermittent‐Induction Regimen and Duration of Short‐Course Treatment for Human Immunodeficiency Virus–Related Pulmonary Tuberculosis
  Clinical Infectious Diseases, 1998
• Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance
  AIDS, 1997
• Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections
  Antimicrobial Agents and Chemotherapy, 1995